Objective: A review of the literature was conducted to elucidate existing information on this topic to assist in clinical decision-making for dermatologists.
Objectives: To evaluate the prevalence of depression in patients with HS.
It is challenging to estimate a true prevalence of hidradenitis suppurativa (HS) because it is underdiagnosed and misdiagnosed.
We aimed to review the most up-to-date information regarding the epidemiology, clinical presentation, diagnostic studies, pathogenesis, comorbidities and quality of life of patients with hidradenitis suppurativa.
Objectives: To measure the impairment of life quality in patients with HS.
Hidradenitis suppurativa is a recurrent, debilitating suppurative skin disease.
In this study, we have reviewed the available antibiotic therapies for HS, analyzing the pharmacologic aspects of these kind of treatments.
In a phase 2 trial, adalimumab, an antibody against tumor necrosis factor α, showed efficacy against hidradenitis suppurativa.
CHMP positive for Awiqli (once-weekly basal insulin icodec) for treatment of diabetes in adults.- Novo Nordisk.
Objective: Evaluate the novel, validated endpoint, Hidradenitis Suppurativa Clinical Response (HiSCR) and its utility as an outcome measure.